All In Biotech

Drug Trial Radar · NCT06131554

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

A Multicenter, Randomized, Double-blinded, Positive-controlled Phase Ⅲ Clinical Trial to Evaluate Lot-to-lot Consistency, Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,480

Actual

Start

Mar 20, 2024

Primary completion

Jul 12, 2024

Study completion Jun 4, 2025

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.

Conditions

  • Meningococcal Meningitis

Interventions

  • batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)Biological

    1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

  • batch 2 of MCV4Biological

    1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

  • batch 3 of MCV4Biological

    1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

  • Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological

    1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The geometric mean titer (GMT) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants.Time frame: Day 30 post vaccination
  2. The seroconversion rate of serogroup A, C, Y, and W135 meningococcal rSBA titer.Time frame: Day 30 post vaccination
  3. The incidence of adverse reactions (ARs) in all participants.Time frame: Within 7 days post vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Husada Utama Hospital

    Surabaya, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.